Trump's FDA pick faces tough questioning from Senate panel

Overton appeared before the Senate during confirmation hearings for the influential federal health agency post, fielding extensive questions from senators seeking clarity on her stance regarding policies rolled out over the past year. The line of questioning reflected broader legislative concerns about the direction of health policy under the current administration, particularly around vaccine-related matters and pharmaceutical regulation.

Senators pressed Overton on her views of existing health protocols and her commitment to the FDA's traditional regulatory standards. The hearing underscored ongoing tensions between the Trump administration's approach to health policy and the Senate's oversight responsibilities in confirming senior agency leadership.

The FDA position ranks among the most consequential health regulatory roles in the United States, overseeing food safety, drug approvals, and medical device standards. Overton's confirmation would place her at the centre of significant decisions affecting public health policy during the remainder of the administration's term.

The Senate is expected to proceed with further deliberations on the nomination in coming weeks, with lawmakers from both sides signalling they intend to thoroughly examine her qualifications and policy positions before any confirmation vote.